| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 144 |
| 13 Nov 2026 | 144 |
| 12 Nov 2026 |
Form 4: Chaudhuri Sarbani, See Remarks
Sold 4,872 shares ($11.3K) |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
FDA alignment establishes path to complete the pivotal Phase 2 trial of RP-A501 in Danon disease; dosing completion expected by mid-2027 |
| 12 Nov 2026 | 10-Q |
| 09 Nov 2026 |
Form 4: Wilson Martin, General Counsel
Sold 53,389 shares ($128K) |
| 09 Nov 2026 | 144 |
| 09 Nov 2026 | 144 |
| 05 Nov 2026 | 144 |
| 30 Oct 2026 | SCHEDULE 13G/A |
| 06 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
THIS LOAN AND SECURITY AGREEMENT is made and dated as of September 30, 2026, and is entered into by and among ROCKET PHARMACEUTICALS, INC., a Delaware corporation (“Company”), its Subsidiaries SPACECRAFT SEVEN, LLC, a Delaware limited li... |
| 15 Sep 2026 |
Form 4: Wilson Martin, General Counsel
Sold 75,364 shares ($256K) |
| 15 Sep 2026 | 144 |
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
FDA confirms pivotal efficacy population of 12 patients, including the first three treated under the modified protocol |
| 14 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
| 02 Sep 2026 | 25-NSE |
| 27 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 20 Aug 2026 |
Form 4: Wilson Martin, General Counsel
Sold 631 shares ($2.13K) |
Loading...